Shopping Cart
- Remove All
Your shopping cart is currently empty
K 00546
😃Good
Catalog No. T21950Cas No. 443798-47-8
Alias K00546
K 00546 is a potent inhibitor of cellular cyclin kinases (CDK1 and CDK2) and CDC2-like kinases (CLK1 and CLK3) used in the study of cancer and immune-related diseases.
K 00546
😃Good
Purity: 99.12%
Catalog No. T21950Alias K00546Cas No. 443798-47-8
K 00546 is a potent inhibitor of cellular cyclin kinases (CDK1 and CDK2) and CDC2-like kinases (CLK1 and CLK3) used in the study of cancer and immune-related diseases.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $98 | 6-8 weeks | |
| 5 mg | $265 | 6-8 weeks | |
| 25 mg | $920 | 6-8 weeks | |
| 50 mg | $1,180 | 6-8 weeks | |
| 100 mg | $1,820 | 6-8 weeks | |
| 1 mL x 10 mM (in DMSO) | $320 | 6-8 weeks |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "K 00546"
Abemaciclib
Cited
LY2835219, CDK4/6 dual inhibitor
T23811231929-97-7
Abemaciclib (LY2835219) is a dual inhibitor of CDK4/6 (IC50=2/10 nM) with selectivity and specificity. Abemaciclib has antitumor activity and is used to treat advanced or metastatic breast cancer.
- $48
Size
QTY
CitedSodium Oxamate Cited
SO, Oxamic acid sodium salt, oxamate sodium, Aminooxoacetic acid sodium salt
T19831565-73-1
Sodium Oxamate (Oxamic acid sodium salt) is an LDH inhibitor that specifically inhibits LDHA. Sodium Oxamate has antitumor activity and induces cell cycle arrest and apoptosis.
- $31
Size
QTY
Cited4-Chloro-2'-bromoacetophenone
T8908536-38-9
4-Chloro-2'-bromoacetophenone against glycogen synthase kinase-3 (GSK-3beta).
- $30
Size
QTY
Ribociclib Cited
LEE011
T61991211441-98-3
Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor (IC50：10/39 nM).
- $36
Size
QTY
CitedCASIN
Pirl1-related Compound 2
T3971425399-05-9
CASIN (Pirl1-related Compound 2) is a specific inhibitor of GTPase Cdc42 (IC50: 2 uM).
- $32
Size
QTY
CHIR-99021 Cited
Laduviglusib, CT99021, CHIR-99021
T2310252917-06-9
CHIR-99021 (CT99021) is an activator of the Wnt/β-catenin signaling pathway and a GSK-3α/β inhibitor (IC50=10/6.7 nM) with selective and oral activity.CHIR-99021 induces cellular autophagy, which enhances self-renewal in mouse and human embryonic stem cells.
- $36
Size
QTY
CitedCromolyn sodium
Sodium cromoglycate, FPL-670, FPL 670 (Cromolyn) Disodium, Disodium Cromoglycate
T126015826-37-6
Cromolyn sodium (FPL-670) is a chromone complex that acts by inhibiting the release of chemical mediators from sensitized mast cells.
- $48
Size
QTY
Dinaciclib Cited
SCH 727965, PS-095760
T1912779353-01-4
Dinaciclib (SCH 727965) is a selective CDK inhibitor targeting CDK1, CDK2, CDK5, and CDK9 (IC50 = 3/1/1/4 nM). It exhibits potential antitumor activity by inhibiting the incorporation of thoracic glycan (dThd) DNA.
- $47
Size
QTY
CitedAbemaciclib methanesulfonate Cited
LY2835219 mesylate, LY2835219 (methanesulfonate), LY2835219, abemaciclib mesylate
T31111231930-82-7
Abemaciclib methanesulfonate (LY2835219) is a specific and effective inhibitor of CDK4(IC50=2 nM) and CDK6(IC50=10 nM).
- $30
Size
QTY
CitedPalbociclib Cited
PD 0332991
T1785571190-30-2
Palbociclib (PD 0332991) is a CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM) and is orally active. Palbociclib has anti-tumorigenic activity and has investigational potential for use in ER-positive and HER2-negative breast cancer.
- $48
Size
QTY
CitedPalbociclib monohydrochloride
PD 0332991 hydrochloride, Palbociclib hydrochloride, Palbociclib (PD-0332991) HCl
T6239827022-32-2
Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.
- $30
Size
QTY
GSK-3 Inhibitor 5
4-Cyanophenacyl bromide
T7755420099-89-2
GSK-3 Inhibitor 5 (4-Cyanophenacyl bromide) is a ketone derivative that is used as an intermediate in pharmaceuticals and organic synthesis, and inhibits glycogen synthase kinase 3 (GSK-3).
- $29
Size
QTY
Select Batch
Purity:99.12%
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | K 00546 is a potent inhibitor of cellular cyclin kinases (CDK1 and CDK2) and CDC2-like kinases (CLK1 and CLK3) used in the study of cancer and immune-related diseases. |
| Targets&IC50 | CLK1:8.9 nM, ERK2:1.0 μM, PDGFRβ:1.6 μM, CLK3:29.2 nM, CDK2-CyclinA:0.5 nM, Calmodulin kinase:8.9 μM, Casein kinase-1:2.8 μM, PKA:5.2 μM, CDK1-CyclinB:0.6 nM, GSK-3:0.14 μM, VEGFR2:0.032 μM |
| In vitro | K 00546 binds to the SLK ATP binding site and forms three hydrogen bonds with the kinase hinge residues E109 and C111. In addition, the aminosulfonyl portion of K 00546 interacts with the backbone of L40. [1] K 00546 also inhibits a number of kinases, including PKA, casein kinase-1, MAP kinase (ERK-2), calmodulin kinase, VEGF-R2, GSK-3, and PDGF-Rβ, with IC50 values of 5.2 μM, 2.8 μM, 1.0 μM, 8.9 μM, 0.032 μM, 0.14 μM, and 1.6 μM, respectively. K 00546 is a potent CDK1 and CDK2 inhibitor with IC50 values of 0.6 nM for CDK1/cyclin B and 0.5 nM for CDK2/cyclin A. [2] K 00546 has also been shown to be a potent CDC2-like kinase 1 (CLK1) and CLK3 inhibitor with IC50 values of 8.9 nM and 29.2 nM, respectively. [3] |
| Alias | K00546 |
| Molecular Weight | 425.44 |
| Formula | C15H13F2N7O2S2 |
| Cas No. | 443798-47-8 |
| Smiles | O=S(=O)(N)C1=CC=C(C=C1)NC=2N=C(N)N(N2)C(=S)NC=3C(F)=CC=CC3F |
| Relative Density. | 1.72 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (188.04 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy K 00546 | purchase K 00546 | K 00546 cost | order K 00546 | K 00546 chemical structure | K 00546 in vitro | K 00546 formula | K 00546 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.